| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $32,551,288 ) (Continued on the next page) |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | P20GM121327 | University of Kentucky Center for Cancer Metabolism | 001 | 9 | NIH | 12/23/2024 | $2,060,688 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K08DK124566 | Muscle bone interaction and its role in diabetic bone disease of Type I diabetes | 000 | 5 | NIH | 12/20/2024 | $164,517 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K01DK128022 | Elucidating Molecular Mechanisms Linking Fructose to Cholesterol Metabolism | 000 | 4 | NIH | 12/20/2024 | $148,186 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AR084282 | Using the gut microbiome to treat skeletal muscle atrophy | 000 | 1 | NIH | 1/27/2025 | $458,907 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | F31HL175979 | PPARgamma Coregulators in Rosiglitazone-Induced Cardiovascular Disease | 000 | 1 | NIH | 12/5/2024 | $34,896 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | F31HL170972 | Bilirubin Catabolism induces Plasminogen-Activator Inhibitor 1 (PAI-1) worsening Metabolic Dysfunction | 000 | 2 | NIH | 12/5/2024 | $34,966 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K23MH126211 | A Precision Medicine Approach to Target Engagement for Emotion Regulation | 000 | 4 | NIH | 1/27/2025 | $110,027 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG079525 | The impact of insulin sensitivity on the potential of metformin to delay age-related inflammation | 000 | 4 | NIH | 3/26/2025 | $399,659 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01NS136272 | Harnessing engineered drug-free polymeric nanoformulations to reprogram innate immune cells for spinal trauma | 000 | 2 | NIH | 2/20/2025 | $293,936 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 South Limestone | Lexington | KY | 40526-0001 | FAYETTE | USA | H7600719 | Ryan White Part C Outpatient EIS Program | 00 | 24 | HRSA | 3/6/2025 | $162,498 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R35HL150818 | Platelet Exocytosis and Endocytosis in Thrombosis and Immunity | 000 | 6 | NIH | 3/27/2025 | $838,047 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01CA249734 | Targeting Lipid Metabolism in Colorectal Cancer | 000 | 5 | NIH | 3/6/2025 | $311,789 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01CA251478 | Local Flavor Policies to Enhance Equity in Tobacco | 000 | 5 | NIH | 4/4/2025 | $430,896 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DA060632 | Advancing Troriluzole as a Treatment for Methamphetamine Use Disorder: A Human Laboratory Study | 000 | 1 | NIH | 4/9/2025 | $634,048 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG037868 | Chronic Stress, Glucocorticoids, and Progesterone in Brain Aging | 000 | 10 | NIH | 4/9/2025 | $354,966 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01HD118715 | Functional Characterization of Genetic Variants in Rare Disease Associated with Shoc2 scaffold | 000 | 1 | NIH | 4/10/2025 | $419,204 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | U01DK135111 | Restoration of Impaired Awareness of Hypoglycemia U01 Consortium: University of Kentucky | 001 | 3 | NIH | 4/10/2025 | $530,098 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21NS137256 | Combinatorial approach to restore breathing after spinal cord injury | 000 | 2 | NIH | 2/20/2025 | $183,637 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21CA301113 | Pathways to Prevention: Exploring Social Determinants of Health in Early Onset Colorectal Cancer | 000 | 1 | NIH | 2/27/2025 | $192,610 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | F31HL170558 | The myosin super-relaxed state and human dilated cardiomyopathy | 000 | 2 | NIH | 4/9/2025 | $35,322 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21AI185681 | Saturating transposon mutagenesis for Chlamydia | 000 | 2 | NIH | 4/14/2025 | $189,966 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21CA285253 | Novel Strategy to Augmenting Immunotherapy against Melanoma | 000 | 2 | NIH | 3/14/2025 | $191,693 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01CA207772 | Roles of Hsp47 in Breast Cancer Progression | 000 | 9 | NIH | 4/18/2025 | $327,038 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R34DA060087 | Optimizing Low Threshold TelePrEP Care in Syringe Service Programs for People who Inject Drugs in Appalachia | 000 | 2 | NIH | 4/22/2025 | $296,530 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | P01AG078116 | Strategies for Targeting Astrocyte Reactivity in Alzheimer's Disease and Related Dementias | 000 | 3 | NIH | 3/14/2025 | $230,000 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01HL171111 | Functional Interactions Between Lipoproteins and Protease Inhibitors in Atherosclerosis | 000 | 2 | NIH | 4/21/2025 | $589,400 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DK113625 | Contributions of Hepatic and Intestinal Pathways to Cholesterol Excretion | 002 | 8 | NIH | 4/15/2025 | $491,578 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DK135885 | Older Adults Using Social Support to Improve Self-Care (OASIS): Adaption, Implementation, and Feasibility of Peer Support for Older Adults with T2DM in Appalachia | 001 | 3 | NIH | 4/21/2025 | $305,547 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG072728 | Emerging Role of Tau Citrullination During Alzheimer’s disease and Tauopathies | 000 | 3 | NIH | 4/14/2025 | $451,452 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01HD115554 | The Impact of Leukocyte-derived Cytokines on Ovulation in Humans | 000 | 2 | NIH | 4/18/2025 | $364,344 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG069909 | The role of satellite cells in skeletal muscle hypertrophy with aging | 001 | 5 | NIH | 4/16/2025 | $323,662 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R61HL177474 | Liposomal azithromycin to treat cardiac inflammation | 000 | 1 | NIH | 3/18/2025 | $542,094 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01CA282254 | Integrative Targeted Therapy for Melanoma | 000 | 2 | NIH | 3/14/2025 | $547,758 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21DA060354 | Regulation of cocaine use by astrocyte voltage-gated channels | 000 | 2 | NIH | 3/18/2025 | $221,887 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R00DA056288 | Neurocognitive Impairments Resulting from Adolescent Prescription Opioid Use Disorder: Longitudinal Impact, Neural Mechanisms, and Comorbidities | 000 | 4 | NIH | 3/17/2025 | $249,000 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG068055 | Identifying Associations between Brain Iron, Neurocognitive Networks and Protective Factors | 000 | 5 | NIH | 3/18/2025 | $487,670 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01NS119165 | Translational Approaches to Mitigate Enhanced Alzheimer’s Disease Risk Following a Mild TBI | 000 | 3 | NIH | 3/12/2025 | $344,250 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01NS121193 | Functional Diversity of Reactive Astrocytes in Spinal Cord Repair | 000 | 5 | NIH | 4/2/2025 | $344,250 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01HL172813 | Circadian Regulation of Cardiac Electrophysiology | 000 | 2 | NIH | 4/2/2025 | $614,817 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AA028246 | Cross-Tailoring Integrative Alcohol and Risky Sex Feedback for College Students: A Hybrid Type 1 Effectiveness-Implementation Trial | 000 | 5 | NIH | 3/19/2025 | $501,404 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01CA258751 | Combating melanoma resistance by targeting ABL1/2 | 000 | 4 | NIH | 4/3/2025 | $524,025 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01NS079507 | Novel Therapeutic Strategies to Resolve Neurovascular Inflammation and Repair Blood-Brain Barrier Dysfunction in Epilepsy | 000 | 11 | NIH | 4/2/2025 | $507,285 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG090534 | Blood-Brain Barrier Dysfunction in Alzheimer’s Disease: New Mechanistic Insights and Therapeutic Strategies | 000 | 1 | NIH | 4/21/2025 | $758,744 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | F30AG079506 | Investigating Enlarged Perivascular Spaces as a Neuroimaging Biomarker of Cerebral Small Vessel Disease | 000 | 3 | NIH | 4/24/2025 | $40,487 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R24OD010435 | Research Resources for Model Amphibians | 000 | 23 | NIH | 2/14/2025 | $406,029 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | F30NS124136 | Elucidating Shared Risk of Brain Arteriolosclerosis and Related Pathologies with Multiple 'omics Modalities | 000 | 4 | NIH | 4/25/2025 | $7,079 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01HL173026 | Investigating the Role of HDL-Associated Serum Amyloid A in Sepsis-Induced Acute Lung Injury and Mortality | 001 | 1 | NIH | 4/25/2025 | $0 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R00CA249048 | A pro-metastatic secretory program activated by epithelial-to-mesenchymal transition | 000 | 4 | NIH | 2/14/2025 | $224,101 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01CA251663 | Targeting Mitochondrial Redox Capacity to Overcome Cancer Subtype that Regrowth After Radiation | 000 | 5 | NIH | 3/3/2025 | $314,989 |
|
